drugset / Trial / NCT07342803
Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multicenter, randomized, masked, active and placebo controlled, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-003 injection in adult patients with moderate to severe persistent allergic asthma.
Timeline
- Start
- 2025-01-25
- Primary completion
- 2027-12-28
- Completion
- 2029-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LP-003 | Unknown | 150 mg | Subcutaneous |
| Subject | LP-003 | Unknown | 300 mg | Subcutaneous |
| Subject | LP-003 | Unknown | 450 mg | Subcutaneous |
| Comparator | Omalizumab | Monoclonal antibody | — | Subcutaneous |